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Background: Studies have demonstrated associations between cytokine gene polymorphisms and the risk of
idiopathic pulmonary fibrosis (IPF). We therefore examined polymorphisms in the genes encoding interleukin (IL)-6,
IL-10, interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and transforming growth factor-beta 1
(TGF-β1), and compared the serum levels of these cytokines in IPF patients and healthy controls. Furthermore, we
examined the association of the studied genotypes and serum cytokine levels with physiological parameters and
the extent of parenchymal involvement determined by high-resolution computed tomography (HRCT).
Methods: Sixty patients with IPF and 150 healthy controls were included. Cytokine genotyping was performed
using the polymerase chain reaction sequence specific primer (PCR-SSP) method. In a subset of patients and
controls, serum cytokine levels were determined by enzyme-linked immunosorbent assay.
Results: There was no difference between IPF patients and controls in the genotype and allele distributions of
polymorphisms in TNF-α, IFN-γ, IL-6, IL-10, and TGF-β1 (all p > 0.05). The TNF-α (−308) GG, IL-6 (−174) GG and CG,
and IL-10 (−1082, -819, -592) ACC ATA genotypes were significantly associated with HRCT scores (all p < 0.05). IL-10
(−1082, -819, -592) ACC haplotype was associated with the diffusion capacity of the lung for carbon monoxide, and
ATA haplotype was associated with the partial pressure of oxygen (PaO2) (all p < 0.05). The TGF-β1 (codons 10 and
25) TC GG, TC GC, CC GG and CC GC genotypes were significantly associated with the PaO2 and HRCT scores
(p < 0.05). The TGF-β1 (codons 10 and 25) CC GG genotype (5 patients) was significantly associated with higher
PaO2 value and less parenchymal involvement (i.e., a lower total extent score) compared to the other TGF-β1
genotypes (81.5 ± 11.8 mm Hg vs. 67.4 ± 11.1 mm Hg, p = 0.009 and 5.60 ± 1.3 vs. 8.51 ± 2.9, p = 0.037, respectively).
Significant differences were noted between patients (n = 38) and controls (n = 36) in the serum levels of IL-6 and
IL-10 (both, p < 0.0001), but not in the levels of TNF-α and TGF-β1 (both, p > 0.05).
Conclusion: The studied genotypes and alleles do not predispose to the development of IPF but appear to play an
important role in disease severity. Our results suggest that the TGF-β1 (codons 10 and 25) CC GG genotype could
be a useful genetic marker for identifying a subset of IPF patients with a favorable prognosis; however, validation in
a larger sample is required.
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Idiopathic pulmonary fibrosis (IPF) is a specific form of
chronic, progressive fibrosing interstitial pneumonia of
unknown cause. It occurs primarily in older adults, and is
associated with the histopathological and/or radiological
pattern of usual interstitial pneumonia [1]. The pathogenesis* Correspondence: esamalhamad@yahoo.com
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initiation of the fibrotic response may depend upon genetic
factors and environmental triggers, and T helper (Th)-1
or Th-2 cell-derived cytokines may be important. More
specifically, there may be an imbalance between pro- and
anti-fibrotic/inflammatory cytokines and growth factors
such as tumor necrosis factor-alpha (TNF-α), transforming
growth factor-beta1 (TGF-β1), interleukin (IL)-1Ra and
IL-6 [2]. The frequencies of polymorphisms in the genes
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polymorphisms of IL-6 and TGF-β1 have been associated
with disease progression [3-9].
Pulmonary function tests and high-resolution computed
tomography (HRCT) are valuable tools for evaluating
patients with IPF. In addition, extent of parenchymal
involvement scores (as determined by HRCT) are important
prognostic markers in IPF patients [10,11]. A previous
study noted that poor scores for total extent of fibrosis,
honeycombing, reticulation and architectural distortion
(all of which reflect advanced stage fibrosis) were signifi-
cantly associated with increased mortality among Saudi
IPF patients [11].
Against this background, we examined polymorphisms in
the genes encoding IL-6, IL-10, interferon gamma (IFN-γ),
TNF-α, and TGF-β1 among Saudi patients newly diagnosed
with IPF, and compared our results with those from healthy
volunteers. The serum levels of IL-6, IL-10, TNF-α and
TGF-β1 were also determined among IPF patients and
controls. Furthermore, we examined the associations of
the studied genotypes and serum cytokine levels with
physiological parameters and the extent of parenchymal
involvement determined by HRCT.
Methods
Study population
Sixty patients with IPF and 150 healthy volunteers solicited
from among the hospital personnel as control subjects
were included in this study, which was performed between
January 2009 and May 2011 at King Khalid University
Hospital, King Saud University, Riyadh, Saudi Arabia. The
study was approved by the Institutional Review Board/
Ethics Committee of the College of Medicine, King Saud
University, Riyadh, Saudi Arabia. Written informed consent
was obtained from each individual included in the study.
IPF was diagnosed according to the American Thoracic
Society/European Respiratory Society consensus classification
[12]. Histopathological evidence of IPF was available for
24 (40%) of patients, while the remaining patients were
diagnosed on the basis of compatible clinical, laboratory
and HRCT findings. Healthy controls were randomly
selected and had no associated medical illness. All subjects
were evaluated as outpatients, and none had clinical
evidence of concurrent infection. None of the patients was
receiving any corticosteroids or other immunosuppressive
medications at the time of blood sample collection. In
addition, none of the patients had any history of acute
exacerbations of IPF within three months of the serum
cytokine measurements.
Thirty patients seen during the study period were
excluded because although their HRCT images were
consistent with usual interstitial pneumonia, they had
positive autoantibodies based on serological tests. These
exclusion criteria included antinuclear antibody titer > 320,rheumatoid factor titer > 60, and/or the presence of
anti-cyclic citrullinated peptide, anti-Ro/SSA, anti-La/SSB,
anti-double-stranded DNA (dsDNA), anti-Smith, anti-
Sclero 70 (Scl-70), anti- ribonucleoprotein (RNP), and
anti-histidyl-tRNA synthetase (Jo-1).
Measurements
Pulmonary function tests (PFT Masterscreen; Jaeger,
Hoechberg, Germany) were performed using standard
methodologies, including spirometry, plethysmography,
and measurement of the diffusion capacity of the lung for
carbon monoxide (DLco) [13-15]. Arterial blood gas values
(Rapid Lab 865; Bayer, Plymouth, UK) were obtained for
the partial pressure of oxygen (PaO2), the partial pressure
of carbon dioxide (PaCO2), and the extent of oxygen
saturation (SaO2).
Chest HRCT
All patients underwent CT scanning (Light Speed 16 or
VCT XT; GE Medical Systems, Milwaukee, WI, USA).
Full-volume scans reconstructed every 2.5 mm were
obtained throughout the entire thorax. Scans were
performed during suspended inspiration with patients
in the supine position. Additional limited scans using
1.25-mm thin collimation at 10-mm intervals from the
aortic arch level to the lung bases, with high spatial reso-
lution reconstruction, were obtained at end-expiration with
patients in the prone position. CT images were assessed
for the presence and extent of parenchymal abnormalities,
including ground-glass opacity, reticular opacity, honey-
combing, traction bronchiectasis, emphysema, and archi-
tectural distortion. The extent of parenchymal abnormality
was determined for each complete lung using a previously
described 5-point scale [16] (0 = no involvement; 1 = 1-25%;
2 = 26-50%; 3 = 51-75%; and 4 = 76-100%). Each lung was
scored separately and divided into three zones (upper
zone, lung apex to aortic arch; middle zone, aortic arch to
a position inferior to the pulmonary veins; and lower zone,
from the inferior pulmonary veins to the diaphragm). A
mean score for each of the six zones was calculated for
each parenchymal pattern (i.e., ground-glass opacity,
reticular opacity, honeycombing, traction bronchiectasis,
emphysema, and architectural distortion). Total lung
involvement was determined by summing the scores for
each CT pattern (total extent).
DNA extraction from peripheral blood
Peripheral blood (8 ml) was drawn and centrifuged with an
acid-citrate-dextrose (ACD) anti-coagulant. DNA extraction
was performed using a QIAamp DNA mini kit (Qiagen
Inc., Valencia, CA, USA) in accordance with the manufac-
turer’s instructions. In brief, cells were lysed with lysis
buffer and proteases, the DNA was ethanol precipitated,
and the sample was transferred to a QIAamp column and
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increase the DNA yield, 200 μl of elution buffer was added
to the column and the sample was incubated for 5 minutes
at room temperature. Finally, the DNA was collected by
centrifugation for 1 minute. The concentration and purity
of the recovered DNA were assessed by spectrophotometry
(GeneQuantII, Pharmacia Biotech, Sweden), and the sample
was stored in elution buffer at −20°C until use.
Cytokine genotyping
The investigated gene polymorphisms included TGF-β1
(codons 10 and 25), IL-6 (−174), IL-10 (−1082, -819
and −592), TNF-α (−308), and IFN-γ (+874). Cytokine
genotyping was performed using the polymerase chain
reaction sequence specific primer (PCR-SSP) method
with a cytokine-genotyping tray (Micro SSP™ primer
set tray; One Lambda Inc., Canoga Park, CA, USA).
DNA samples were thawed at room temperature and
mixed with D-mix and recombinant Taq polymerase. The
mixture was dispensed to the tray and amplification was
performed in a thermocycler (Perkin Elmer 9700; Perkin
Elmer, Foster City, CA, USA) using the following program:
denaturation at 96°C for 2 minutes, 9 cycles of 96°C for
10 seconds and 63°C for 50 seconds, and then 20 cycles of
96°C for 10 seconds, 59°C for 50 seconds and 72°C for
30 seconds. The amplified DNA products were resolved by
electrophoresis and identified using a gel-documentation
system (Alpha Inotech, Santa Clara, CA, USA).
Serum cytokine assay
Due to resource limitations, blood samples were collected
from the first consecutively enrolled IPF patients (n = 38)
and healthy controls (n = 36). Cytokines were assessed in
serum samples by quantitative sandwich immunoassays
performed on a fully automated ELISA machine (ETI-Max
3000; DiasORIN S.p.A, Vercelli, Italy) using ELISA kits
purchased from R&D Systems (Minneapolis, MN, USA).
Estimation of each cytokine was performed in accordance
with the manufacturers’ instructions. Briefly, 50 μl of assay
diluent was dispensed to each well, and 200 μl of standard,
control or serum sample were added as appropriate. The
contents were incubated at room temperature for 2 hours,
washed four times with washing buffer, and mixed with
200 μl of cytokine conjugate per well. After a further incu-
bation for 2 hours at room temperature, the plate was
washed and 200 μl of substrate was dispensed to each
well. The plate was then incubated for 20 minutes at room
temperature, and 50 μl of stop solution was added to each
well. Optical densities were recorded and the results were
expressed in pg/ml.
Statistical analysis
Data are presented as proportions, means and standard
deviations for normally distributed data, or as median(range) for non-normally distributed data. Allele and
genotype frequencies were calculated by direct counting.
Observed and expected frequencies were compared
using the chi-square test or Fisher’s exact test to check for
Hardy-Weinberg equilibrium (HWE). Differences between
genotype and allele frequencies in IPF patients and controls
were analyzed with the chi-square or Fisher’s exact tests.
Odds ratios and 95% confidence intervals for relative risks
were calculated. One-way analysis of variance (ANOVA)
and the Student’s t-test were used to compare the means of
quantitative variables (age, physiological parameters and
HRCT scores) in relation to various genotypes and serum
cytokines level. For nonparametric data (serum cytokine
levels between patients and controls), the Mann–Whitney
U test was used. Pearson’s and Spearman’s correlation
coefficients were used for parametric and nonparametric
data, respectively, to examine the relationship between
serum cytokine levels and quantitative variables. A two-
sided p value < 0.05 was considered statistically significant.
All analyses were performed using the Statistical Software
Package for the Social Sciences (SPSS, version 16.0; SPSS
Inc., Chicago, IL, USA).
Results
The 150 healthy controls included 75 males and 75
females with a mean age of 30.8 ± 9.6 years. Among the
60 IPF patients, the mean age was 61.1 ± 12.9 years;
there was a slight predominance of males (33; 55%), and
the male-to-female ratio was 1.22:1. The demographic
and clinical characteristics of the IPF patients are shown
in Table 1. As expected, restrictive ventilatory defects
with markedly decreased diffusion capacities of the lung
for carbon monoxide were commonly noted among the
IPF patients.
The distributions of the observed genotypes were not
significantly different from the expected distribution
according to HWE (Table 2) (all p > 0.05).
The distributions of the different cytokine genotypes
and alleles in the IPF and healthy control groups are
shown in Tables 3, 4 and 5. There was no significant
difference in the genotype or allele distributions of poly-
morphisms in TNF-α (−308), IFN-γ (+874), IL-6 (−174),
IL-10 (−1082, -819 and −592), and TGF-β1 (codons 10
and 25) between the IPF and healthy control groups
(all p > 0.05).
The associations of the studied genotypes/alleles with
the physiological parameters and CT scores for the extent
of parenchymal abnormalities are shown in Tables 6 and 7.
Patients with the TNF-α (−308) GG genotype had a
higher mean score for honeycombing compared to those
with the other TNF-α (−308) genotypes (1.51 ± 0.61 vs.
1.17 ± 0.57, respectively, p = 0.036), whereas patients with
the TNF-α (−308) AG genotype tended to have a lower
honeycombing extent score compared to those with the
Table 1 Demographic and clinical characteristics of IPF
patients and healthy controls
Characteristics Patients (n = 60) Healthy controls
Age at presentation, years 61.1 ± 12.9 30.8 ± 9.6
Male/Female 33/27 75/75
Disease duration, months 32.6 ± 12.9 -
Ever smoker, n (%) 20 (33.3) 34 (22.6)
Baseline PFTs
FVC,% predicted 61.7 ± 21.9 -
FEV1,% predicted 69.8 ± 23.8 -
TLC,% predicted 57.5 ± 18.7 -
DLco,% predicted 38.1 ± 21.3 -
Baseline ABG
PaO2, mmHg 68.6 ± 11.7 -
PaCO2, mmHg 41.1 ± 6.0 -
SaO2,% 93.9 ± 3.7 -
HRCT scores
Total extent 8.3 ± 3.0 -
Ground glass opacity 1.4 ± 0.8 -
Reticulation 1.6 ± 0.7 -
Honeycombing 1.4 ± 0.6 -
Traction Bronchiectasis 2.1 ± 1.0 -
Architectural distortion 1.2 ± 0.8 -
Emphysema 0.4 ± 0.8 -
Data are presented as means ± standard deviations or number
(with percentages).
Abbreviations: IPF idiopathic pulmonary fibrosis, PFTs pulmonary function
tests, ABG arterial blood gas, FVC forced vital capacity, FEV1 forced expiratory
volume in 1 second, TLC total lung capacity, DLco diffusion capacity of lung for
carbon monoxide, PaO2 partial pressure of oxygen, PaCO2 partial pressure of
carbon dioxide, SaO2 oxygen saturation and HRCT high-resolution
computed tomography.
Table 2 Hardy-Weinberg equilibrium tests for the
investigated cytokine gene polymorphisms among the
healthy controls
Cytokine/genotype Observed Expected *p-value
TNF-α (−308)
AA 6.0 3.5 0.274
AG 25.3 30.3 0.304
GG 68.7 66.2 0.622
IFN-γ (+874)
TT 23.3 22.7 0.891
AT 48.7 49.9 0.817
AA 28.0 27.4 0.897
IL-6 (−174)
CC 6.0 2.9 0.156
CG 22.0 28.2 0.230
GG 72.0 68.9 0.612
IL-10 (−1082, -819, -592)
GCC GCC 18.7 16.0 0.542
GCC ACC 20.7 22.4 0.674
GCC ATA 22.0 25.6 0.497
ACC ACC 10.7 7.8 0.472
ACC ATA 14.0 17.9 0.345
ATA ATA 14.0 10.2 0.286
TGF-β1 (codons 10 and 25)
TT GG 31.3 26.3 0.373
TC GG 35.3 37.6 0.719
TC GC 10.0 13.5 0.368
CC GG 18.0 12.3 0.199
TT GC 0 0 -
CC GC 4.7 8.8 0.164
CC CC 0.7 1.4 0.562
TT CC 0 0 -
TC CC 0 0 -
Data are presented as percentages.
Abbreviations: TNF-α tumor necrosis factor alpha, IFN-γ interferon gamma, IL
interleukin and TGF-β1 transforming growth factor beta 1.
* Chi-square or Fisher’s exact tests were used to compare frequencies between
observed and expected genotypes.
Alhamad et al. BMC Medical Genetics 2013, 14:66 Page 4 of 13
http://www.biomedcentral.com/1471-2350/14/66other TNF-α (−308) genotypes (1.16 ± 0.60 vs. 1.49 ± 0.59,
respectively, p = 0.052). Furthermore, honeycombing
extent score tended to be lower in patients with the
TNF-α (−308) A allele versus the G allele (1.19 ± 0.56 vs.
1.44 ± 0.62, respectively, p = 0.055).
The mean ground glass opacity score was significantly
higher for the IL-6 (−174) GG genotype versus the
other IL-6 (−174) genotypes (1.58 ± 0.89 vs. 1.00 ± 0.54,
respectively, p = 0.021), whereas the IL-6 (−174) CG
genotype was associated with significantly lower ground
glass opacity extent scores compared to the other IL-6
(−174) genotypes (0.91 ± 0.54 vs. 1.55 ± 0.87, respectively,
p = 0.022). Moreover, the IL-6 (−174) C allele was signifi-
cantly associated with lower ground glass opacity and
reticulation extent scores versus the G allele (1.05 ± 0.52
vs. 1.50 ± 0.88, p = 0.032 and 1.26 ± 0.65 vs. 1.64 ± 0.69,
p = 0.028, respectively).
Patients with the IL-10 (−1082, -819, -592) ACC ATA
genotype had significantly higher honeycombing extentscores compared to those with the other IL-10 (−1082, -
819, -592) genotypes (1.88 ± 0.64 vs. 1.31 ± 0.58, p = 0.014).
The IL-10 (−1082, -819, -592) ACC haplotype was asso-
ciated with higher DLco value compared to the other
haplotypes (43.18 ± 24.11% predicted vs. 32.38 ± 17.99%
predicted, p = 0.030), and the ATA haplotype was associated
with a lower PaO2 than the other haplotypes (65.58 ±
11.14 mm Hg vs. 71.74 ± 12.12 mmHg, p = 0.018).
Exploring the association of TGF-β1 (codons 10 and 25)
with physiological parameters and CT scores revealed
several significant findings. The TGF-β1 (codons 10 and
Table 3 Comparison of genotype and allele frequencies




IPF Healthycontrols *p-value OR 95% CI
(n = 60) (n = 150)
TNF-α (−308)
AAa 4 (6.7) 9 (6) 0.856 0.894 0.264 – 3.020
AGb 19 (31.7) 38 (25.3) 0.392 0.732 0.380 – 1.412
GGc 37 (61.7) 103 (68.7) 0.336 1.362 0.730 – 2.544
A alleled 27 (22.5) 56 (18.7) 0.416 0.791 0.471 – 1.327
G allele 93 (77.5) 244 (81.3)
IFN-γ (+874)
TTe 15 (25) 35 (23.3) 0.858 0.913 0.455 – 1.832
ATf 23 (38.3) 73 (48.7) 0.220 1.525 0.828 – 2.810
AAg 22 (36.7) 42 (28) 0.247 0.672 0.356 – 1.267
T alleleh 53 (44.2) 143 (47.7) 0.588 0.868 0.567 – 1.329
A allele 67 (55.8) 157 (52.3)
IL-6 (−174)
CCi 4 (6.7) 9 (6) 0.856 0.894 0.264 – 3.020
CGj 11 (18.3) 33 (22) 0.708 1.256 0.588 – 2.685
GGk 45 (75) 108 (72) 0.733 0.857 0.432 – 1.699
C allelel 19 (15.8) 51 (17) 0.885 1.089 0.612 – 1.935
G allele 101 (84.2) 249 (83)
Data are presented as number (with percentages).
Abbreviations: TNF-α tumor necrosis factor alpha, IFN-γ interferon gamma, IL
interleukin, IPF idiopathic pulmonary fibrosis, OR odds ratio, CI
confidence interval.
*Chi-square or Fisher’s exact tests were used to compare frequencies between
genotypes and alleles.
aAA vs. GG and AG genotypes.
bAG vs. AA and GG genotypes.
cGG vs. AG and AA genotypes.
dA vs. G allele.
eTT vs. AT and AA genotypes.
fAT vs. AA and TT genotypes.
gAA vs. TT and AT genotypes.
hT vs. A allele.
iCC vs. GG and CG genotypes.
jCG vs. CC and GG genotypes.
kGG vs. CG and CC genotypes.
lC vs. G allele.
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higher ground glass opacity extent score compared to the
other TGF-β1(codons 10 and 25) genotypes (1.75 ± 0.79
vs. 1.22 ± 0.83, p = 0.017), and the TGF-β1 (codons 10 and
25) TC GC genotype was associated with a lower PaO2
than the other TGF-β1 (codons 10 and 25) genotypes
(55.16 ± 4.13 mm Hg vs. 69.32 ± 11.59 mmHg, p = 0.041).
In contrast, the TGF-β1 (codons 10 and 25) CC GG
genotype was associated with a higher PaO2 and less
parenchymal involvement (i.e., a lower total extent score)
compared to the other TGF-β1 (codons 10 and 25)
genotypes (81.50 ± 11.86 mm Hg vs. 67.44 ± 11.11 mmHg, p = 0.009 and 5.60 ± 1.34 vs. 8.51 ± 2.99, p = 0.037,
respectively). The CC GC genotype was associated with a
lower ground glass opacity score compared to the other
genotypes (0.33 ± 0.57 vs. 1.49 ± 0.83, p = 0.02), and the
TGF-β1 (codons 10 and 25) G allele was associated with
higher PaO2 values than the C allele (69.26 ± 11.75 mm
Hg vs. 59.46 ± 5.82 mm Hg, p = 0.021).
Comparisons of serum cytokine levels in patients (n = 38)
and controls (n = 36) are shown in Figure 1.
Among the IPF patients, the serum levels of IL-6
[median 4.03 pg/ml (range 0.00 – 32.35 pg/ml), p < 0.0001]
and IL-10 [median 3.56 pg/ml (range 0.00 – 12.17 pg/ml),
p < 0.0001] were significantly higher than those in the
healthy controls [median 0.00 pg/ml (range 0.00 –
267.38 pg/ml) for IL-6 and median 0.8 pg/ml (range
0.00 – 7.56 pg/ml for IL-10)].
There was no significant difference in the serum levels
of TNF-α between the IPF patients and controls [median
3.3 pg/ml (range 0.00 - 26.90 pg/ml and median 10.6 pg/ml
(range 0.00 – 64.07 pg/ml), respectively; p = 0.499]. In
addition, we found no significant difference in the serum
levels of TGF-β1 between IPF patients and controls
[median 13.7 pg/ml (range 0.00 - 253.84 pg/ml) and
median 10.2 pg/ml (range 2.67 – 37.15 pg/ml), respectively;
p = 0.127].
The biochemical serum characteristics of the IPF pa-
tients and healthy controls in relation to their genotypes
(high, intermediate, and low producers) are shown in
Table 8.
The relationship between serum levels of IL-10 and
IL-10 haplotype-carrier state were examined. The serum
levels of IL-10 were not significantly different among the
IPF who carried the GCC haplotype [median 3.56 pg/ml
(range 0.00 – 11.27 pg/ml)] compared with the levels in
GCC haplotype-negative patients [median 4.50 pg/ml
(range 0.00 – 12.16 pg/ml)] (p = 0.701). Furthermore, no
significant difference in the serum levels of IL-10 among
the IPF who carried the ACC haplotype [median
3.56 pg/ml (range 0.00 – 7.16 pg/ml)] compared with
the levels in ACC haplotype-negative patients [median
4.50 pg/ml (range 0.00 – 12.16 pg/ml)] (p = 0.281).
Moreover, no significant difference in the serum levels
of IL-10 among the IPF who carried the ATA haplotype
[median 3.56 pg/ml (range 0.00 – 12.16 pg/ml)] compared
with the levels in ATA haplotype-negative patients
[median 3.61 pg/ml (range 0.00 – 11.27 pg/ml)] (p = 0.988).
Among the healthy controls no significant difference in
serum levels of IL-10 were noted in relation to IL-10
haplotypes (data not shown).
Correlation analysis did not show any significant rela-
tionship between the studied serum cytokine levels and
the physiological parameters or CT scores for the extent
of parenchymal abnormalities in our IPF patients (data
not shown).
Table 4 Comparison of genotype, haplotype carrier rate, haplotype carrier frequencies and allele frequencies for IL-10
in IPF patients and healthy controls
IL-10 (−1082, -819, -592) IPF (n = 60) Healthy controls (n = 150) *p-value OR 95% CI
Genotype
GCC GCCa 10 (16.7) 28 (18.7) 0.844 1.148 0.519 – 2.537
GCC ACCb 13 (21.7) 31 (20.7) 0.853 0.942 0.454 – 1.955
GCC ATAc 14 (23.3) 33 (22) 0.856 0.927 0.455 – 1.889
ACC ACCd 7 (11.7) 16 (10.7) 0.811 0.904 0.352 – 2.322
ACC ATAe 8 (13.3) 21 (14) 1.000 1.058 0.441 – 2.540
ATA ATAf 8 (13.3) 21 (14) 1.000 1.058 0.441 – 2.540
Haplotype carrier rate
GCC carriers 37 (61.7) 92 (61.3) 0.964 0.986 0.533 – 1.825
ACC carriers 28 (46.7) 68 (45.3) 0.861 0.948 0.520 – 1.728
ATA carriers 30 (50) 75 (50) 1.000 1.000 0.549 – 1.820
Haplotype frequency
GCC 0.392 0.400 0.935 1.021 0.616 – 1.693
ACC 0.292 0.280 0.737 0.916 0.549 – 1.528
ATA 0.316 0.320 0.993 0.998 0.602 – 1.653
Allele
−1082 G alleleg 47 (39.2) 120 (40) 0.912 0.966 0.626 – 1.489
A allele 73 (60.8) 180 (60)
−819 C alleleh 82 (68.3) 204 (68) 1.000 1.015 0.644 – 1.600
T allele 38 (31.7) 96 (32)
−592 C allelei 82 (68.3) 204 (68) 1.000 1.015 0.644 – 1.600
A allele 38 (31.7) 96 (32)
Data are presented as number (with percentages).
Abbreviations: IL interleukin, IPF idiopathic pulmonary fibrosis, OR odds ratio, CI confidence interval.
*Chi-square or Fisher’s exact tests were used to compare frequencies between genotypes and alleles.
aGCC GCC vs. other IL-10 genotypes.
bGCC ACC vs. other IL-10 genotypes.
cGCC ATA vs. other IL-10 genotypes.
dACC ACC vs. other IL-10 genotypes.
eACC ATA vs. other IL-10 genotypes.
fATA ATA vs. other IL-10 genotypes.
gG vs. A allele.
hC vs. T allele.
iC vs. A allele.
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In the present study, we observed significant associations
between TNF-α, IL-6, IL-10, and TGF- β1 polymorphisms
and PaO2, DLco and HRCT scores. Furthermore, the
serum cytokine levels of IL-6 and IL-10 were significantly
higher in IPF patients compared to healthy controls.
IPF is a disabling fibroproliferative disorder characterized
by progressive fibrosis of the interstitial spaces of the
lung, resulting in destruction of the normal parenchymal
architecture [17]. Despite extensive research, the cause of
IPF is still unknown. Substantial evidence in animal models
and humans supports the hypothesis that there is an im-
balance between Th-1 and Th-2 cytokines, with an excess
of Th-2 cytokines being associated with the development
of lung fibrosis [2,18,19].IL-10 is a T-cell-derived cytokine of the Th-2 family
that is known to suppress inflammation by inhibiting a
number of pro-inflammatory cytokines [20]. Moreover,
IL-10 has been shown to induce the generation of a
high-IL-10-producing subset of CD4+ T cells, called
regulatory T cells, that are capable of down-regulating
antigen-specific immune responses [21]. The pro-fibrotic
activity of IL-10 is currently under debate, as experimental
studies have reported both anti-fibrotic [22] and pro-fibrotic
[23] activities. Martinez and colleagues [24] noted that
alveolar macrophages recovered from bronchoalveolar
lavage (BAL) in patients with pulmonary fibrosis showed
increased IL-10 mRNA expression. Notably, however, these
patients had lower IL-10 protein levels in their BAL fluid
(BALF) compared to healthy control subjects. Our study
Table 5 Comparison of genotype and allele frequencies for TGF-β1 in IPF patients and healthy controls
Cytokine/genotype/allele IPF (n = 60) Healthy controls (n = 150) *p-value OR 95% CI
TGF-β1 (codons 10 and 25)
TT GGa 24 (40) 47 (31.3) 0.260 0.684 0.368 – 1.274
TC GGb 24 (40) 53 (35.3) 0.530 0.820 0.443 – 1.517
TC GCc 3 (5) 15 (10) 0.289 2.111 0.588 – 7.575
CC GGd 5 (8.3) 27 (18) 0.091 2.415 0.883 – 6.602
TT GC 0 0 -
CC GCe 3 (5) 7 (4.7) 0.918 0.930 0.232 – 3.723
CC CCf 1 (1.7) 1 (0.7) 0.500 0.396 0.024 – 6.435
TT CC 0 0 -
TC CC 0 0 -
Codon 10 T alleleg 75 (62.5) 162 (54) 0.128 1.420 0.920 – 2.191
C allele 45 (37.5) 138 (46)
Codon 25 G alleleh 112 (93.3) 276 (92) 0.839 1.217 0.531 – 2.791
C allele 8 (6.7) 24 (8)
Data are presented as number (with percentages).
Abbreviations: TGF-β1 transforming growth factor beta, IPF idiopathic pulmonary fibrosis, OR odds ratio, CI confidence interval;
*Chi-square or Fisher’s exact tests were used to compare frequencies between genotypes and alleles.
aTT GG vs. other TGF-β1 genotypes.
bTC GG vs. other TGF-β1 genotypes.
cTC GC vs. other TGF-β1 genotypes.
dCC GG vs. other TGF-β1 genotypes.
eCC GC vs. other TGF-β1 genotypes.
fCC CC vs. other TGF-β1 genotypes.
gT vs. C allele.
hG vs. C allele.
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http://www.biomedcentral.com/1471-2350/14/66confirms the findings of Tsoutsou et al. [25] that IL-10 is
markedly increased in the sera of IPF patients compared
to healthy controls. The clinical significance of the high
levels of IL-10 observed in IPF patients is unclear, as we
found no association between serum IL-10 levels and
physiological parameters or the extent of parenchymal
abnormalities based on CT scores among the IPF patients.
Nevertheless, we found that the IL-10 (−1082, -819, -592)
ACC ATA genotype was significantly associated with a
higher honeycombing extent score (i.e., a less favorable
outcome) compared to the other IL-10 genotypes. In
addition, the IL-10 (−1082, -819, -592) ACC haplotype
was associated with higher DLco value compared to the
other haplotypes, and the ATA haplotype was associated
with a lower PaO2 than the other haplotypes. As such, it is
possible that IL-10-mediated induction of regulatory T
cells in IPF patients may play a role in the disease process.
This will require further investigation.
In agreement with the reports of Riha et al. [6] and
Vasakova et al. [8], we found no difference in the distribu-
tion of IL-6 alleles or genotypes between IPF patients and
controls. IL-6 displays a broad range of activities, partici-
pating in the acute phase response and the stimulation
and differentiation of T and B cells [26,27]. Although most
nucleated cells produce IL-6, its secretion by fibroblasts
stimulates the proliferation of cells in an autocrine/paracrine manner, suggesting that IL-6 is one of the key
cytokines that promote fibrogenesis [28,29]. Pantelidis
et al. [5] noted that the IL-6 intron 4 GG genotype was
with lower levels of DLco (as a marker for disease progres-
sion) among a cohort of IPF patients from the United
Kingdom. In the present study, interestingly, the GG
genotype was associated with a significantly higher ground
glass opacity score (i.e., active disease) compared to the
CG genotype. Furthermore, the IL-6 (−174) C allele was
significantly associated with lower ground glass opacity
and reticulation scores versus the G allele, implying that
IL-6 plays an important role in disease severity. The
association between hypoxia and serum IL-6 levels in IPF
patients was explored by Tsantes et al. [30], who noted
that patients with profound hypoxemia (PaO2 < 65 mm
Hg) had significantly higher serum IL-6 levels compared
to healthy controls. In the present study, we found no
differences in IL-6 levels between patients with PaO2 <
65 mm Hg or PaO2 > or equal to 65 mm Hg (data not
shown), suggesting that mechanisms other than hypoxia
are involved in IL-6 secretion in IPF patients. Moreover,
we found no correlation between serum IL-6 levels and
physiological parameters or CT scores in our IPF patients.
However, we observed markedly elevated serum IL-6
levels in IPF patients compared to controls, implying that
these patients remain in a persistent inflammatory state
Table 6 Associations of TNF-α, IFN-γ, and IL-6 polymorphisms with physiological parameters and HRCT scores in IPF
patients
Cytokine/genotype/ †p-value
Allele PaO2 FVC, % P DLco,% P Total extent GGO Retic HC AD Emphy
TNF-α (−308)
GGa 0.670 0.397 0.663 0.214 0.348 0.361 0.036* 0.147 0.164
AGb 0.563 0.937 0.845 0.407 0.371 0.670 0.052 0.107 0.333
AAc 0.806 0.132 0.643 0.387 0.873 0.326 0.656 0.860 0.372
ANOVA 0.839 0.303 0.859 0.415 0.638 0.512 0.108 0.273 0.346
A alleled 0.803 0.179 0.578 0.161 0.397 0.238 0.055 0.262 0.125
G allele
IFN-γ (+874)
TTe 0.574 0.725 0.913 0.769 0.603 0.916 0.904 0.924 0.861
ATf 0.923 0.552 0.572 0.736 0.211 0.875 0.938 0.543 0.860
AAg 0.547 0.360 0.652 0.939 0.430 0.950 0.852 0.484 0.983
ANOVA 0.791 0.659 0.842 0.933 0.460 0.987 0.982 0.763 0.979
T alleleh 0.443 0.392 0.808 0.896 0.824 0.982 0.838 0.586 0.925
A allele
IL-6 (−174)
GGi 0.236 0.654 0.346 0.138 0.021* 0.109 0.719 0.503 0.861
CGj 0.213 0.530 0.332 0.325 0.022* 0.502 0.674 0.663 0.686
CCk 0.901 0.844 0.860 0.300 0.659 0.083 0.198 0.626 0.351
ANOVA 0.444 0.817 0.600 0.309 0.057 0.148 0.425 0.785 0.623
C allelel 0.288 0.777 0.379 0.078 0.032* 0.028* 0.352 0.420 0.547
G allele
Abbreviations: TNF-α tumor necrosis factor alpha, IFN-γ interferon gamma, IL interleukin, HRCT high-resolution computed tomography, IPF idiopathic pulmonary
fibrosis, PaO2 partial pressure oxygen, FVC,% P forced vital capacity, percent predicted, DLco diffusion capacity of lung for carbon monoxide, GGO ground glass
opacity, Retic reticulation, HC honeycombing, AD architectural distortion, Emphy emphysema.
† One-way analysis of variance (ANOVA) and the Student’s t-test were used to compare the means of quantitative variables.
* Statistically significant.
aGG vs. AG and AA genotypes.
bAG vs. AA and GG genotypes.
cAA vs. GG and AG genotypes.
dA vs. G allele.
eTT vs. AT and AA genotypes.
fAT vs. AA and TT genotypes.
gAA vs. TT and AT genotypes.
hT vs. A allele.
iGG vs. CG and CC genotypes.
jCG vs. CC and GG genotypes.
kCC vs. GG and CG genotypes.
lC vs. G allele.
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http://www.biomedcentral.com/1471-2350/14/66despite the advanced stage of fibrosis. Recently, Collard
et al. [31] noted that serum IL-6 and other biomarkers of
type II alveolar epithelial cells (KL-6 and SP-D) were
significantly higher among IPF patients with acute exacer-
bation compared to stable IPF patients and those with
acute lung injury. Together, the findings in the present
and previous studies indicate that IL-6 may be a marker
for disease progression. Future studies will be needed to
explore its role in the pathogenesis of pulmonary fibrosis.
TGF-β, which is produced by a wide variety of cell types,
is one of the key cytokines involved in the pathogenesis of
pulmonary fibrosis. TGF-β1 possesses a broad spectrum ofactivities; it is chemotactic for fibroblasts, acts as a potent
inducer of extracellular matrix synthesis, and can stimulate
protease inhibitor expression [32]. Up-regulation of TGF-β
gene and protein expression has been documented in lung
tissues from patients with IPF and in an animal model of
pulmonary fibrosis [33-35]. Furthermore, antibodies against
TGF-β1 were found to decrease bleomycin-induced pul-
monary fibrosis, further substantiating the role of this
cytokine in pulmonary fibrosis [36]. In studying IPF patients
of Han ethnicity, Li et al. [37] found an association between
the TGF-β1 869 > C polymorphism and the development
of IPF. In the present study, however, we did not find that
Table 7 Association of IL-10 and TGF-β1 polymorphisms with physiological parameters and HRCT scores in IPF patients
Cytokine/genotype/ †p-value
Allele PaO2 FVC, % P DLco,% P Total extent GGO Retic HC AD Emphy
IL-10 (−1082, -819, -592)
GCC GCCa 0.389 0.262 0.948 0.098 0.137 0.935 0.514 0.334 0.173
GCC ACCb 0.583 0.286 0.411 0.278 0.552 0.853 0.619 0.171 0.778
GCC ATAc 0.390 0.905 0.710 0.564 0.741 0.942 0.501 0.539 0.962
ACC ACCd 0.252 0.456 0.531 0.437 0.341 0.536 0.658 0.884 0.460
ACC ATAe 0.533 0.354 0.390 0.171 0.837 0.069 0.014* 0.081 0.388
ATA ATAf 0.319 0.730 0.058 0.695 0.837 0.147 0.203 0.820 0.635
ANOVA 0.587 0.661 0.469 0.333 0.698 0.416 0.173 0.393 0.719
GCC haplotypeg 0.606 0.472 0.517 0.497 0.120 0.415 0.769 0.681 0.333
ACC haplotypeh 0.312 0.293 0.030* 0.329 0.080 0.326 0.440 0.767 0.101
ATA haplotypei 0.018* 0.862 0.097 0.802 0.799 0.858 0.769 0.907 0.783
−1082 G allelej 0.461 0.499 0.830 0.438 0.144 0.876 0.996 0.881 0.200
A allele
−819 C allelek 0.053 0.841 0.066 0.941 0.914 0.542 0.617 0.793 0.988
T allele
−592 C allelel 0.053 0.841 0.066 0.941 0.914 0.542 0.617 0.793 0.988
A allele
TGF-β1(codons 10 and 25)
TT GGm 0.902 0.161 0.548 0.690 0.462 0.708 0.734 0.839 0.711
TC GGn 0.967 0.290 0.663 0.509 0.017* 0.708 0.734 0.892 0.951
TC GCo 0.041* 0.119 0.217 0.876 0.240 0.528 0.270 0.732 0.444
CC GGp 0.009* 0.372 0.526 0.037* 0.238 0.201 0.146 0.248 0.314
TT GC
CC GCq 0.128 0.858 0.101 0.412 0.020* 0.291 0.074 0.059 0.945
CC CCr 0.911 0.083 0.539 0.451 0.090 0.403 0.533 0.122 0.050
TT CC
TC CC
ANOVA 0.025* 0.157 0.408 0.359 0.010* 0.586 0.246 0.210 0.382
Codon 10 T alleles 0.662 0.076 0.441 0.315 0.319 0.543 0.701 0.760 0.738
C allele
Codon 25 G allelet 0.021* 0.687 0.027* 0.890 0.053 0.726 0.968 0.800 0.370
C allele
Abbreviations: IL interleukin, TGF- β1 transforming growth factor beta, HRCT high-resolution computed tomography, IPF idiopathic pulmonary fibrosis, PaO2 partial
pressure of oxygen, FVC,% P forced vital capacity, percent predicted, DLco diffusion capacity of the lung for carbon monoxide, GGO ground glass opacity, Retic
reticulation, HC honeycombing, AD architectural distortion, Emphy emphysema.
† One-way analysis of variance (ANOVA) and the Student’s t-test were used to compare the means of quantitative variables.
* Statistically significant.
aGCC GCC vs. other IL-10 genotypes.
bGCC ACC vs. other IL-10 genotypes.
cGCC ATA vs. other IL-10 genotypes.
dACC ACC vs. other IL-10 genotypes.
eACC ATA vs. other IL-10 genotypes.
fATA ATA vs. other IL-10 genotypes.
gGCC vs. other IL-10 haplotypes.
hACC vs. other IL-10 haplotypes.
iATA vs. other IL-10 haplotypes.
jG vs. A allele.
kC vs. T allele.
lC vs. A allele.
mTT GG vs. other TGF-β1 genotypes.
nTC GG vs. other TGF-β1 genotypes.
oTC GC vs. other TGF-β1 genotypes.
pCC GG vs. other TGF-β1 genotypes.
qCC GC vs. other TGF-β1 genotypes.
rCC CC vs. other TGF-β1 genotypes.
sT vs. C allele.
tG vs. C allele.
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Figure 1 Serum levels of interleukin (IL)-6, IL-10, transforming growth factor-beta 1 (TGF-β1), and tumor necrosis factor alpha (TNF-α)
in idiopathic pulmonary fibrosis (IPF) patients (n = 38) and healthy controls (n = 36). Each circle represents one individual, and transverse
lines indicate median values. P-values were determined using the nonparametric Mann–Whitney U test.
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http://www.biomedcentral.com/1471-2350/14/66TGF-β1 gene polymorphisms predisposed Saudi patients
to develop IPF. This is in agreement with reports from
other regions, including Spanish [9], Australian [6], and
Czech [8] populations. Nonetheless, the lack of association
between TGF-β1 gene polymorphisms and the disease
does not rule out the clinical importance of this cytokine
in the ongoing scarring observed in IPF patients. Xaubet
and colleagues [9] noted that the presence of the proline-
encoding allele at codon 10 of TGF-β1 in IPF patients was
associated with a significant increase in alveolar arterial
oxygen tension difference during follow-up, compared to
IPF patients without the proline-encoding allele. In the
present study, the associations of the TGF-β1 (codons 10
and 25) TC GG, TC GC, CC GG, and CC GC genotypes
with PaO2 and the extent of parenchymal involvement
(as assessed by HRCT) suggest that TGF-β1 plays an
important role in determining disease severity. The CC
GG genotype is particularly interesting in this respect,
as it was significantly associated with a higher PaO2
value and a lower total extent score. Relatively few patients
harbored this genotype (n = 5) in the present study,
making it difficult to draw a firm conclusion. Future
work will be required to validate our findings in a
larger sample and examine whether this genotype could
be used to identify a subset of IPF patients with a more
favorable prognosis.Plasma levels of TGF-β1 have been shown to be under
genetic control [38]. In IPF patients, the plasma levels of
TGF-β1 were previously noted to be higher than those
of controls [39,40]. However, Molina-Molina et al. [39]
reported that changes in TGF-β1 levels did not correlate
with changes in lung function parameters in IPF patients
monitored over time. Here, we found no significant
difference in the serum level of TGF-β1 between patients
and controls. Also, consistent with the previous report
[39], the serum levels of TGF-β1 did not correlate with
any clinical parameter (e.g., pulmonary function tests,
arterial blood gas values and CT scores) in our IPF
patients.
TNF-α is a proinflammatory cytokine that plays a central
role in stimulating cell-cell adhesion and transendothelial
migration, as well as in the early events of the cytokine and
chemokine production cascade [41]. Increased expression
of TNF-α has been found in the lung tissues of humans
and animal models of pulmonary fibrosis, and adminis-
tration of a neutralizing anti-TNF-α antibody to an
animal model was shown to attenuate pulmonary
indicating that TNF-α is an important cytokine in the
pathogenesis of lung fibrosis [41,42]. TNF-α polymor-
phisms have been significantly associated with an increased
risk of IPF among Italians and Australians, but not in
British and Czech populations [3,5,6,8]. In the current
Table 8 Serum cytokine levels in relation to their genotypes and alleles among IPF patients and healthy controls
Cytokine/genotype/ Allele Producer n IPF n Healthy controls *p-value
TNF-α
GG Low 21 1.37 (0 – 19.68) 24 11.22 (0 – 64.07) 0.226
GA High 13 6.82 (0 – 26.90) 12 8.64 (0 – 11.58) 0.511
AA High 4 9.99 (1.27 – 13.10) -
G allele 34 2.35 (0 – 26.9) 36 10.81 (0 – 64.07) 0.194
A allele 17 7.89 (0 – 26.9) 12 8.64 (0 – 11.58) 0.293
IL-6
GG High 27 3.44 (0 – 32.35) 24 0 (0 – 267.38) <0.0001
GC High 8 6.45 (0.57 – 15.41) 8 0 (0 – 0.58) <0.0001
CC Low 3 14.1 (4.80 – 16.11) 4 0 0.057
G allele 35 3.61 (0 – 32.35) 32 0 (0 – 267.38) <0.0001
C allele 11 9.52 (0.57 – 16.11) 12 0 (0 – 0.58) <0.0001
IL-10
GCC GCC High 6 4.99 (0 – 11.27) 7 0.56 (0 – 2.03) 0.031
GCC ACC Intermediate 8 3.61 (0 – 7.16) 6 1.44 (0 – 3.38) 0.090
GCC ATA Intermediate 9 3.48 (0 – 9.48) 8 0.10 (0 – 7.56) 0.077
ACC ACC Low 6 4.05 (0 – 6.52) 7 1.58 (0 – 4.92) 0.221
ACC ATA Low 3 2.99 (0.72 – 3.56) 4 1.54 (0 – 6.74) 0.721
ATA ATA Low 6 4.92 (0.80 – 12.16) 4 0.57 (0 – 5.13) 0.087
GCC haplotype 23 3.56 (0 – 11.27) 21 0.41 (0 – 7.56) 0.001
ACC haplotype 17 3.56 (0 – 7.16) 17 1.48 (0 – 6.74) 0.067
ATA haplotype 18 3.56 (0 – 11.27) 16 0.10 (0 – 7.56) 0.011
−1082 G allele 23 3.56 (0 – 11.27) 21 0.48 (0 – 7.56) <0.0001
A allele 32 3.58 (0 – 12.16) 29 1.09 (0 – 7.56) <0.0001
−819 C allele 32 3.56 (0 – 11.27) 32 1.22 (0 – 7.56) <0.0001
T allele 18 4.50 (0 – 12.16) 16 0.10 (0 – 7.56) 0.002
−592 C allele 32 3.56 (0 – 11.27) 32 1.22 (0 – 7.56) <0.0001
A allele 18 4.50 (0 – 12.16) 16 0.10 (0 – 7.56) 0.002
TGF-β1
TT GG High 14 18.98 (0 – 253.84) 13 10.34 (2.67 – 19.34) 0.058
TC GG High 17 9.7 (0.16 – 185.28) 12 10.23 (5.27 – 21.21) 0.929
TC GC Intermediate 3 12.95(3.44 – 70.94) 5 8.04 (3.96 – 37.15) 0.881
CC GG Intermediate 3 6.32 (4.5 – 13.72) 5 10.58 (6.06 – 13.19) 0.655
TT GC Intermediate - -
CC GC Low 1 16.35 1 6.91 0.317
CC CC Low - -
TT CC Low - -
TC CC Low - -
Codon 10 T allele 34 14.87 (0 – 253.84) 30 10.34 (2.67 – 37.15) 0.023
C allele 24 11.32 (0.16 – 185.28) 23 10.11 (3.96 – 37.15) 0.949
Codon 25 G allele 38 13.33 (0 – 253.84) 23 10.34 (2.67 – 37.15) 0.067
C allele 4 14.65 (3.44 – 70.94) 19 7.47 (3.96 – 37.15) 0.670
Data presented as median (range) in pg/ml. n = number of patients.
Abbreviations: TNF-α tumor necrosis factor alpha, IL interleukin, and TGF-β1 transforming growth factor beta.
*Nonparametric Mann–Whitney U test.
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http://www.biomedcentral.com/1471-2350/14/66study, we found no difference in the distribution of
TNF-α alleles and genotypes between IPF patients and
controls. However, the TNF-α (−308) GG genotype was
significantly associated with a higher honeycombing
extent score, whereas the TNF-α (−308) AG genotype
tended to be associated with a lower honeycombing
extent score. This suggests that TNF-α polymorphisms
may play an important role in disease severity.
IFN-γ is a Th-1 cytokine that plays pivotal roles in
modulating immune responses; it can inhibit fibroblast
proliferation and has been shown to reduce extracellular-
matrix deposition in animal models of fibrosis [43]. Previ-
ously, IFN-γ was found to be decreased in the sera and
lung tissues of IPF patients [25,44]. However, in agreement
with the findings of Latsi et al. [45] and Vasakova et al. [8],
we found no association between IFN-γ polymorphisms
and IPF in our Saudi population.
Conclusion
In conclusion, we herein identified associations between
TNF-α, IL-6, IL-10, and TGF- β1 polymorphisms and
PaO2, DLco, and HRCT scores in IPF patients, implying
that these factors may play important roles in modulating
disease severity. The TGF-β1 (codons 10 and 25) CC GG
genotype, which was present in a relatively small propor-
tion of patients compared to the controls, was associated
with decreased disease severity. Further studies will be
needed to evaluate the potential protective effect of this
genotype against severe IPF.
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